ciprofloxacin has been researched along with Acute Bacterial Prostatitis in 77 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To explore the potential therapeutic benefit of roxithromycin in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), this study compared the effect of roxithromycin with ciprofloxacin and aceclofenac." | 9.19 | Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. ( Cho, YH; Choe, HS; Han, CH; Lee, SJ; Shim, BS, 2014) |
| "Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis." | 9.16 | Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. ( Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC, 2012) |
| "Compound ciprofloxacin suppository combined with Ningbitai and Yunnan Baiyao capsules can significantly decrease the level of serum PSA and relieve related symptoms in III A histological prostatitis with PSA elevation, and Yunnan Baiyao capsules can significantly enhance the therapeutic effect." | 9.16 | [Compound ciprofloxacin suppository combined with ningbitai and yunnan baiyao for histological prostatitis with PSA elevation]. ( Huang, BX; Su, HC; Sun, FK, 2012) |
| "We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin." | 9.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 9.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "Tc-99m ciprofloxacin imaging is helpful in the differential diagnosis of prostatitis syndrome." | 9.10 | Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis. ( Choe, W; Kim, S; Lee, SM; Moon, Y; Pai, SH; Ryu, JK; Seong, DW; Suh, JK, 2003) |
| "The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany." | 9.09 | Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000) |
| "Thirty two patients with proven chronic bacterial prostatitis were treated with ciprofloxacin 500 mg twice daily orally for four weeks." | 9.06 | Treatment of chronic bacterial prostatitis with ciprofloxacin. ( de Leur, EJ; Ferwerda, WH; Hoogkamp-Korstanje, JA; Langemeyer, TN; Schipper, JJ; van der Wal, T; van Oort, H, 1987) |
| "In a one-year follow-up study, short-term therapy with ciprofloxacin proved to be beneficial in the treatment of chronic bacterial prostatitis, particularly in cases of Escherichia coli prostatitis." | 9.06 | Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. ( Dalhoff, A; Schiefer, HG; Weidner, W, 1987) |
| "The objectives of this study were to investigate risk factors and the incidence of ciprofloxacin resistance and extended-spectrum beta-lactamases (ESBL) in patients with acute bacterial prostatitis (ABP)." | 7.83 | Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea. ( Lee, DG; Lee, SH; Lee, Y; Yoo, KH, 2016) |
| ", exhibiting previous failure, patient side effects, or resistance to ciprofloxacin and co-trimoxazole) chronic bacterial prostatitis infections (5 patients with multidrug-resistant Enterobacteriaceae [MDRE]) receiving fosfomycin-tromethamine at a dose of 3 g per 48 to 72 h for 6 weeks." | 7.81 | Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis. ( Almirante, B; Andreu, A; Fernández-Hidalgo, N; Larrosa, N; Los-Arcos, I; Pigrau, C; Rodríguez-Pardo, D, 2015) |
| "Our model implies that ciprofloxacin 500 mg twice daily for 28 days appears to be the most cost effective treatment for chronic bacterial prostatitis." | 7.71 | Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. ( Kaplan, S; Kurzer, E, 2002) |
| "The emergence and evolution of quinolone-resistant Escherichia coli in faeces of patients with prostatitis treated with high-dose oral ciprofloxacin for 1 month were studied." | 7.71 | Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. ( Horcajada, JP; Martínez, JA; Mensa, J; Moreno-Martínez, A; Ruiz, J; Sánchez, M; Soriano, E; Vila, J, 2002) |
| "Bilateral achilles tendinitis developed in a 40-year-old man following treatment with Ciprofloxacin, 500 mg twice a day, for prostatis." | 7.69 | [Ciprofloxacin-associated bilateral acute achilles tendinitis]. ( Arlazoroff, A; Halperin, N; Mirovsky, Y; Pollack, L, 1995) |
| "As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study." | 7.68 | Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993) |
| "A total of 16 men suffering from refractory chronic bacterial prostatitis caused by Escherichia coli was treated with ciprofloxacin for 4 weeks." | 7.68 | Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months. ( Brähler, E; Schiefer, HG; Weidner, W, 1991) |
| "Ciprofloxacin was used for the treatment of refractory chronic bacterial prostatis." | 6.67 | Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin. ( Schiefer, HG; Weidner, W, 1991) |
| "The antibiotic treatment rate of chronic bacterial prostatitis (CBP) is low, and long-term administration can result in adverse events and bacterial resistance." | 5.38 | Preventive effect of selenium on chronic bacterial prostatitis. ( Cho, YH; Ha, US; Kim, HW; Kim, SJ; Lee, SJ; Woo, JC; Yoon, BI, 2012) |
| " However, the treatment outcome is not ideal and long-term administration of antibiotics can result in adverse effects and bacterial resistance." | 5.35 | Synergistic effect between lycopene and ciprofloxacin on a chronic bacterial prostatitis rat model. ( Cho, YH; Han, CH; Kang, SH; Kim, SW; Sohn, DW; Yang, CH, 2008) |
| " To explore the potential therapeutic benefit of roxithromycin in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), this study compared the effect of roxithromycin with ciprofloxacin and aceclofenac." | 5.19 | Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. ( Cho, YH; Choe, HS; Han, CH; Lee, SJ; Shim, BS, 2014) |
| "Compound ciprofloxacin suppository combined with Ningbitai and Yunnan Baiyao capsules can significantly decrease the level of serum PSA and relieve related symptoms in III A histological prostatitis with PSA elevation, and Yunnan Baiyao capsules can significantly enhance the therapeutic effect." | 5.16 | [Compound ciprofloxacin suppository combined with ningbitai and yunnan baiyao for histological prostatitis with PSA elevation]. ( Huang, BX; Su, HC; Sun, FK, 2012) |
| "Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis." | 5.16 | Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. ( Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC, 2012) |
| "We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin." | 5.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 5.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "Tc-99m ciprofloxacin imaging is helpful in the differential diagnosis of prostatitis syndrome." | 5.10 | Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis. ( Choe, W; Kim, S; Lee, SM; Moon, Y; Pai, SH; Ryu, JK; Seong, DW; Suh, JK, 2003) |
| "The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany." | 5.09 | Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000) |
| "Thirty two patients with proven chronic bacterial prostatitis were treated with ciprofloxacin 500 mg twice daily orally for four weeks." | 5.06 | Treatment of chronic bacterial prostatitis with ciprofloxacin. ( de Leur, EJ; Ferwerda, WH; Hoogkamp-Korstanje, JA; Langemeyer, TN; Schipper, JJ; van der Wal, T; van Oort, H, 1987) |
| "In a one-year follow-up study, short-term therapy with ciprofloxacin proved to be beneficial in the treatment of chronic bacterial prostatitis, particularly in cases of Escherichia coli prostatitis." | 5.06 | Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. ( Dalhoff, A; Schiefer, HG; Weidner, W, 1987) |
| "The objectives of this study were to investigate risk factors and the incidence of ciprofloxacin resistance and extended-spectrum beta-lactamases (ESBL) in patients with acute bacterial prostatitis (ABP)." | 3.83 | Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea. ( Lee, DG; Lee, SH; Lee, Y; Yoo, KH, 2016) |
| "The study included 50 patients with chronic prostatitis who showed hot uptake in seminal vesicles on Tc-99m ciprofloxacin imaging and eight patients who did not show hot uptake." | 3.81 | Chronic bacterial seminal vesiculitis as a potential disease entity in men with chronic prostatitis. ( Choe, WS; Choo, GY; Chung, YG; Hyun, IY; Kim, CH; Park, SH; Ryu, DS; Ryu, JK; Seong, DH; Suh, JK, 2015) |
| ", exhibiting previous failure, patient side effects, or resistance to ciprofloxacin and co-trimoxazole) chronic bacterial prostatitis infections (5 patients with multidrug-resistant Enterobacteriaceae [MDRE]) receiving fosfomycin-tromethamine at a dose of 3 g per 48 to 72 h for 6 weeks." | 3.81 | Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis. ( Almirante, B; Andreu, A; Fernández-Hidalgo, N; Larrosa, N; Los-Arcos, I; Pigrau, C; Rodríguez-Pardo, D, 2015) |
| "Men with prostatitis-like symptoms and any bacteria localized to prostate specific specimens were treated with levofloxacin or ciprofloxacin for 4 weeks with 6 months of followup." | 3.74 | Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. ( Nickel, JC; Xiang, J, 2008) |
| "Our model implies that ciprofloxacin 500 mg twice daily for 28 days appears to be the most cost effective treatment for chronic bacterial prostatitis." | 3.71 | Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. ( Kaplan, S; Kurzer, E, 2002) |
| "The emergence and evolution of quinolone-resistant Escherichia coli in faeces of patients with prostatitis treated with high-dose oral ciprofloxacin for 1 month were studied." | 3.71 | Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. ( Horcajada, JP; Martínez, JA; Mensa, J; Moreno-Martínez, A; Ruiz, J; Sánchez, M; Soriano, E; Vila, J, 2002) |
| "Bilateral achilles tendinitis developed in a 40-year-old man following treatment with Ciprofloxacin, 500 mg twice a day, for prostatis." | 3.69 | [Ciprofloxacin-associated bilateral acute achilles tendinitis]. ( Arlazoroff, A; Halperin, N; Mirovsky, Y; Pollack, L, 1995) |
| "As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study." | 3.68 | Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993) |
| "A total of 16 men suffering from refractory chronic bacterial prostatitis caused by Escherichia coli was treated with ciprofloxacin for 4 weeks." | 3.68 | Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months. ( Brähler, E; Schiefer, HG; Weidner, W, 1991) |
| "Ciprofloxacin was used for the treatment of refractory chronic bacterial prostatis." | 2.67 | Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin. ( Schiefer, HG; Weidner, W, 1991) |
| "Ciprofloxacin is a new quinolone derivative which is particularly well adapted for the treatment of bacterial urinary tract infection." | 2.37 | Ciprofloxacin in management of urinary tract infection. ( Rubin, RH; Tolkoff-Rubin, NE, 1988) |
| "We present a unique case of acute bacterial prostatitis caused by a very rare human pathogen, Raoultella planticola, in a renal allograft recipient 3." | 1.40 | Acute prostatitis caused by Raoultella planticola in a renal transplant recipient: a novel case. ( Bakalis, A; Belesiotou, E; Drakopoulos, S; Kalatzis, V; Koukoulaki, M; Papastamopoulos, V; Skoutelis, A, 2014) |
| "The antibiotic treatment rate of chronic bacterial prostatitis (CBP) is low, and long-term administration can result in adverse events and bacterial resistance." | 1.38 | Preventive effect of selenium on chronic bacterial prostatitis. ( Cho, YH; Ha, US; Kim, HW; Kim, SJ; Lee, SJ; Woo, JC; Yoon, BI, 2012) |
| "Traditional first-line treatment of chronic bacterial prostatitis (CBP) is administration of empirical antibiotics." | 1.37 | Do Escherichia coli extract and cranberry exert preventive effects on chronic bacterial prostatitis? Pilot study using an animal model. ( Cho, YH; Ha, US; Han, CH; Kim, HW; Kim, SH; Lee, CB; Lee, HR; Lee, SJ; Sohn, DW, 2011) |
| "Bacterial prostatitis is documented at a very low prevalence (7-13% of prostatitis overall considered) due to either reduced utilization of viral and bacteriological tests (Meares test, urethral swab, bacterial and viral PCR) or to the possibility that individual patients show a scarce expression of bacterial disease in biological fluids, because of intraglandular biofilm presence, with subsequent spreading of the sole plankton microrganisms." | 1.35 | [Chronic prostatitis and biofilm]. ( Bartoletti, R; Cai, T, 2009) |
| " However, the treatment outcome is not ideal and long-term administration of antibiotics can result in adverse effects and bacterial resistance." | 1.35 | Synergistic effect between lycopene and ciprofloxacin on a chronic bacterial prostatitis rat model. ( Cho, YH; Han, CH; Kang, SH; Kim, SW; Sohn, DW; Yang, CH, 2008) |
| " Plasma concentration curves were simulated from literature values of the pharmacokinetic parameters of the drug and the age and weight of the patients." | 1.31 | Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients. ( Coloma Milano, C; Sánchez Navarro, MD; Sánchez-Navarro, A; Sayalero Marinero, ML; Zarzuelo Castañeda, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (9.09) | 18.7374 |
| 1990's | 10 (12.99) | 18.2507 |
| 2000's | 40 (51.95) | 29.6817 |
| 2010's | 20 (25.97) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elshal, AM | 1 |
| Atwa, AM | 1 |
| El-Nahas, AR | 1 |
| El-Ghar, MA | 1 |
| Gaber, A | 1 |
| Elsawy, E | 1 |
| Hashem, A | 1 |
| Farag, Y | 1 |
| Farg, H | 1 |
| Elsorougy, A | 1 |
| Fouda, M | 1 |
| Nabeeh, H | 1 |
| Mosbah, A | 1 |
| Newman, AJ | 1 |
| Mullens, D | 1 |
| Lin, CC | 1 |
| Barr, J | 1 |
| Choe, HS | 1 |
| Lee, SJ | 6 |
| Han, CH | 7 |
| Shim, BS | 2 |
| Cho, YH | 8 |
| Koukoulaki, M | 1 |
| Bakalis, A | 1 |
| Kalatzis, V | 1 |
| Belesiotou, E | 1 |
| Papastamopoulos, V | 1 |
| Skoutelis, A | 1 |
| Drakopoulos, S | 1 |
| Park, SH | 1 |
| Ryu, JK | 2 |
| Choo, GY | 1 |
| Chung, YG | 1 |
| Seong, DH | 1 |
| Kim, CH | 1 |
| Choe, WS | 1 |
| Ryu, DS | 1 |
| Hyun, IY | 1 |
| Suh, JK | 4 |
| Grillo-Puertas, M | 1 |
| Martínez-Zamora, MG | 1 |
| Rintoul, MR | 1 |
| Soto, SM | 1 |
| Rapisarda, VA | 1 |
| Los-Arcos, I | 1 |
| Pigrau, C | 1 |
| Rodríguez-Pardo, D | 1 |
| Fernández-Hidalgo, N | 1 |
| Andreu, A | 1 |
| Larrosa, N | 1 |
| Almirante, B | 1 |
| Diamandis, EP | 1 |
| Lee, Y | 1 |
| Lee, DG | 1 |
| Lee, SH | 1 |
| Yoo, KH | 1 |
| Boeri, L | 1 |
| Fontana, M | 1 |
| Gallioli, A | 1 |
| Zanetti, SP | 1 |
| Catellani, M | 1 |
| Longo, F | 1 |
| Mangiarotti, B | 2 |
| Montanari, E | 3 |
| Sohn, DW | 4 |
| Jung, YS | 1 |
| Kim, SI | 1 |
| Kim, SW | 3 |
| Gültuna, S | 1 |
| Köklü, S | 1 |
| Arhan, M | 1 |
| Aydin, F | 1 |
| Mesci, P | 1 |
| Usküdar, O | 1 |
| Berger, RE | 1 |
| Panagopoulos, P | 1 |
| Antoniadou, A | 1 |
| Kanellakopoulou, K | 1 |
| Tsiodras, S | 1 |
| Katsarolis, I | 1 |
| Papadopoulos, A | 1 |
| Galani, L | 1 |
| Giamarellou, H | 1 |
| Bartoletti, R | 2 |
| Cai, T | 2 |
| Kim, SH | 2 |
| Ha, US | 4 |
| Lee, HR | 1 |
| Kim, HW | 3 |
| Lee, CB | 1 |
| Ekici, S | 1 |
| Cengiz, M | 1 |
| Turan, G | 1 |
| Alış, EE | 1 |
| Mazzoli, S | 1 |
| Meacci, F | 1 |
| Boddi, V | 1 |
| Mondaini, N | 1 |
| Malossini, G | 1 |
| Magri, V | 4 |
| Škerk, V | 3 |
| Markotić, A | 2 |
| Marras, E | 3 |
| Restelli, A | 1 |
| Naber, KG | 4 |
| Perletti, G | 4 |
| Woo, JC | 1 |
| Kim, SJ | 1 |
| Yoon, BI | 1 |
| Fonteyne, V | 1 |
| Ost, P | 1 |
| Villeirs, G | 1 |
| Oosterlinck, W | 1 |
| Impens, A | 1 |
| De Gersem, W | 1 |
| De Wagter, C | 1 |
| De Meerleer, G | 1 |
| Kolumbić Lakos, A | 1 |
| Maleković, G | 1 |
| Dujnić Spoljarević, T | 1 |
| Kovacic, D | 1 |
| Pasini, M | 1 |
| Zhang, ZC | 1 |
| Jin, FS | 1 |
| Liu, DM | 1 |
| Shen, ZJ | 1 |
| Sun, YH | 1 |
| Guo, YL | 1 |
| Huang, BX | 1 |
| Su, HC | 1 |
| Sun, FK | 1 |
| Kurzer, E | 1 |
| Kaplan, S | 1 |
| Sánchez Navarro, MD | 1 |
| Coloma Milano, C | 1 |
| Zarzuelo Castañeda, A | 1 |
| Sayalero Marinero, ML | 1 |
| Sánchez-Navarro, A | 1 |
| Horcajada, JP | 3 |
| Vilana, R | 1 |
| Moreno-Martínez, A | 2 |
| Alvarez-Vijande, R | 1 |
| Bru, C | 1 |
| Bargalló, X | 1 |
| Buñesch, L | 1 |
| Martínez, JA | 2 |
| Mensa, J | 2 |
| Mateos, JJ | 1 |
| Lomena, F | 1 |
| Velasco, M | 1 |
| Ortega, M | 1 |
| Fuertes, S | 1 |
| Pons, F | 1 |
| Schönwald, S | 1 |
| Krhen, I | 1 |
| Banaszak, A | 1 |
| Begovac, J | 1 |
| Strugar, J | 1 |
| Strapac, Z | 1 |
| Vrsalovic, R | 1 |
| Vukovic, J | 1 |
| Tomas, M | 1 |
| Choe, W | 3 |
| Kan Ryu, J | 2 |
| Kim, WH | 2 |
| Chung, MH | 2 |
| Cao, W | 1 |
| Liu, L | 1 |
| Tong, MH | 1 |
| Lee, SM | 1 |
| Seong, DW | 1 |
| Kim, S | 2 |
| Moon, Y | 1 |
| Pai, SH | 1 |
| Bundrick, W | 1 |
| Heron, SP | 1 |
| Ray, P | 1 |
| Schiff, WM | 1 |
| Tennenberg, AM | 2 |
| Wiesinger, BA | 1 |
| Wright, PA | 1 |
| Wu, SC | 2 |
| Zadeikis, N | 1 |
| Kahn, JB | 2 |
| Ginsburg, AS | 1 |
| Woolwine, SC | 1 |
| Hooper, N | 1 |
| Benjamin, WH | 1 |
| Bishai, WR | 1 |
| Dorman, SE | 1 |
| Sterling, TR | 1 |
| Peters, HJ | 1 |
| Breitling, P | 1 |
| Baker, SD | 1 |
| Horger, DC | 1 |
| Keane, TE | 1 |
| Alexander, RB | 2 |
| Propert, KJ | 2 |
| Schaeffer, AJ | 3 |
| Landis, JR | 2 |
| Nickel, JC | 3 |
| O'Leary, MP | 1 |
| Pontari, MA | 1 |
| McNaughton-Collins, M | 1 |
| Shoskes, DA | 1 |
| Comiter, CV | 1 |
| Datta, NS | 1 |
| Fowler, JE | 1 |
| Nadler, RB | 1 |
| Zeitlin, SI | 1 |
| Knauss, JS | 1 |
| Wang, Y | 1 |
| Kusek, JW | 2 |
| Nyberg, LM | 2 |
| Litwin, MS | 2 |
| Weidner, W | 6 |
| Lee, YS | 1 |
| Kang, SH | 2 |
| Shin, OR | 1 |
| Sim, YC | 1 |
| Wyss Lustenberger, R | 1 |
| Makaryus, AN | 1 |
| Byrns, K | 1 |
| Makaryus, MN | 1 |
| Natarajan, U | 1 |
| Singer, C | 1 |
| Goldner, B | 1 |
| Olapade-Olaopa, EO | 1 |
| Adebayo, SA | 1 |
| Serretta, V | 1 |
| Catanese, A | 1 |
| Daricello, G | 1 |
| Liotta, R | 1 |
| Allegro, R | 1 |
| Martorana, A | 1 |
| Aragona, F | 1 |
| Melloni, D | 1 |
| Trinchieri, A | 2 |
| Del Nero, A | 1 |
| Zirpoli, P | 1 |
| de Eguileor, M | 1 |
| Ceriani, I | 2 |
| Vral, A | 1 |
| Kulovac, B | 1 |
| Aganović, D | 1 |
| Prcić, A | 1 |
| Hadziosmanović, O | 1 |
| Yang, CH | 1 |
| Kim, ME | 1 |
| Kim, CS | 1 |
| Lee, SD | 1 |
| Xiang, J | 1 |
| Kertes, P | 1 |
| Goncalves, F | 1 |
| Stefancik, J | 1 |
| Dubravicky, J | 1 |
| Hladik, M | 1 |
| Breza, J | 1 |
| Hoogkamp-Korstanje, JA | 2 |
| van Oort, HJ | 1 |
| Schipper, JJ | 2 |
| van der Wal, T | 2 |
| Grekas, D | 1 |
| Thanos, V | 1 |
| Dioudis, C | 1 |
| Alivanis, P | 1 |
| Tourkantonis, A | 1 |
| Frisolone, J | 1 |
| Manzo, J | 1 |
| Leviton, IM | 1 |
| Mirovsky, Y | 1 |
| Pollack, L | 1 |
| Arlazoroff, A | 1 |
| Halperin, N | 1 |
| Menown, IB | 1 |
| McKane, WR | 1 |
| Kennedy, JA | 1 |
| Kelly, IM | 1 |
| Maclennan, BA | 1 |
| Best, BG | 1 |
| Walsh, MY | 1 |
| Ludwig, M | 1 |
| Brähler, E | 2 |
| Schiefer, HG | 4 |
| Busch, W | 1 |
| Focht, J | 1 |
| Vila, J | 1 |
| Ruiz, J | 1 |
| Sánchez, M | 1 |
| Soriano, E | 1 |
| Oliphant, CM | 1 |
| Green, GM | 1 |
| Jin Kang, K | 1 |
| Aagaard, J | 1 |
| Gasser, T | 1 |
| Rhodes, P | 1 |
| Madsen, PO | 1 |
| Childs, SJ | 1 |
| Boerema, JB | 1 |
| Guibert, J | 1 |
| Destrée, D | 1 |
| Konopka, C | 1 |
| Acar, J | 1 |
| Dalhoff, A | 2 |
| Tolkoff-Rubin, NE | 1 |
| Rubin, RH | 1 |
| Langemeyer, TN | 1 |
| Ferwerda, WH | 1 |
| de Leur, EJ | 1 |
| van Oort, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01843946] | 75 participants (Actual) | Observational | 2011-03-31 | Completed | |||
| A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis[NCT00236808] | Phase 3 | 383 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| A Randomized Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients[NCT00103402] | Phase 3 | 272 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Ciprofloxacin or Tamsulosin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Randomized, Double-blind Trial[NCT04552431] | Phase 2 | 196 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)[NCT00499317] | 500 participants (Anticipated) | Observational | 2007-01-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For the Hospital Anxiety and Depression Scale, higher scores indicate greater anxiety and depression; range, 0 to 42. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alfuzosin | -2.6 |
| Placebo | -1.5 |
For the International Index of Erectile Function, higher scores indicate better sexual function; range, 0 to 75. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alfuzosin | 0.5 |
| Placebo | -0.2 |
For the Male Sexual Health Questionnaire, higher scores indicate better function with respect to erection and ejaculation and greater satisfaction with sexual life; range, 0 to 40. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alfuzosin | 1.7 |
| Placebo | 0.6 |
For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI) total score, higher scores indicate more severe symptoms and scores range from 0 to 43. The primary outcome was a decline of at least 4 from baseline to 12 weeks (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Alfuzosin | 68 |
| Placebo | 66 |
For the Medical Outcomes Study Short Form Health Survey 12 (SF-12), higher scores indicate better quality of life. Score range for both the physical and mental component summaries is 0 to 100. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Physical component | Mental component | |
| Alfuzosin | 3.0 | 4.0 |
| Placebo | 3.5 | 1.9 |
For the McGill Pain Questionnaire, higher scores indicate greater pain. Score ranges are as follows: total score, 0 to 45; sensory score, 0 to 33; affective score, 0 to 12. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Total score | Sensory score | Affective score | |
| Alfuzosin | -3.4 | -2.5 | -1.0 |
| Placebo | -3.1 | -2.3 | -0.9 |
For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI), higher scores indicate more severe symptoms (for the quality-of-life score, higher scores indicate a more negative effect). Score ranges are as follows: total score, 0 to 43; pain score, 0 to 21; urinary score, 0 to 10, quality-of-life score, 0 to 12; and average pain and urgency scores, 0 to 10. (NCT00103402)
Timeframe: Baseline and12 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Total score | Pain score | Urinary score | Quality-of-life score | |
| Alfuzosin | -7.1 | -3.3 | -1.2 | -1.2 |
| Placebo | -6.5 | -3.0 | -1.0 | -1.2 |
4 reviews available for ciprofloxacin and Acute Bacterial Prostatitis
| Article | Year |
|---|---|
Levofloxacin in the treatment of urinary tract infections and prostatitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug | 2004 |
Quinolones: a comprehensive review.
Topics: Ciprofloxacin; Drug Interactions; Humans; Male; Prostatitis; Quinolones; Respiratory Tract Diseases; | 2002 |
Ciprofloxacin in treatment of chronic bacterial prostatitis.
Topics: Chronic Disease; Ciprofloxacin; Humans; Male; Prostatitis | 1990 |
Ciprofloxacin in management of urinary tract infection.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Male; Microbial Sensitivity Tests; Prostatitis; Urinary | 1988 |
22 trials available for ciprofloxacin and Acute Bacterial Prostatitis
| Article | Year |
|---|---|
Chemoprophylaxis during transrectal prostate needle biopsy: critical analysis through randomized clinical trial.
Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Large-Core Needle; Bloo | 2018 |
Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial.
Topics: Adult; Chronic Disease; Ciprofloxacin; Diclofenac; Humans; Male; Pelvic Pain; Pilot Projects; Prospe | 2014 |
Improving positioning in high-dose radiotherapy for prostate cancer: safety and visibility of frequently used gold fiducial markers.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Cone-Beam Com | 2012 |
A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Drug Therapy, Combination; Follow-U | 2011 |
Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients.
Topics: Adult; Anti-Bacterial Agents; Asian People; Ciprofloxacin; Escherichia coli Infections; Humans; Levo | 2012 |
[Compound ciprofloxacin suppository combined with ningbitai and yunnan baiyao for histological prostatitis with PSA elevation].
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Drug Therapy, Combination; Drugs, Chinese Herbal; Hum | 2012 |
Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Fluoroquinolones | 2002 |
Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis.
Topics: Adolescent; Adult; Aged; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Chronic Disease; | 2003 |
Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis.
Topics: Adult; Aged; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Male; Middle Aged; Organo | 2003 |
Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Double-Blind Met | 2003 |
[Antibiotic prophylaxis in transrectal prostate biopsy. Short-term vs. long-term therapy].
Topics: Aged; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Cross Infection; Drug Administration Sc | 2003 |
Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Double-B | 2004 |
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; | 2005 |
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Biopsy, Needle; Ciprofloxacin; Diagnosis, Differenti | 2008 |
Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Doxazosin; Drug Therapy, Combination; | 2007 |
Value of antibiotic therapy for bioptically proved chronic prostatitis.
Topics: Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Humans; Male; Prostate-Specific Antigen; Pros | 2008 |
Outcome of antibiotic therapy with ciprofloxacin in chronic bacterial prostatitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Humans; Male; Middle Aged; | 1999 |
Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Chronic Dis | 2000 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin.
Topics: Ciprofloxacin; Escherichia coli Infections; Follow-Up Studies; Humans; Male; Prostatitis | 1991 |
Treatment of chronic bacterial prostatitis with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials as | 1987 |
Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Escherichia coli Infections; F | 1987 |
51 other studies available for ciprofloxacin and Acute Bacterial Prostatitis
| Article | Year |
|---|---|
Subacute cutaneous lupus erythematosus observed with ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Pro | 2018 |
Acute prostatitis caused by Raoultella planticola in a renal transplant recipient: a novel case.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Gram-Negative Aerobic Bacteria; Gram-Negative Bacterial | 2014 |
Chronic bacterial seminal vesiculitis as a potential disease entity in men with chronic prostatitis.
Topics: Adult; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Male; Middle Aged; Organotechne | 2015 |
Environmental phosphate differentially affects virulence phenotypes of uropathogenic Escherichia coli isolates causative of prostatitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Cellulose; Ciprofloxacin; Escheric | 2015 |
Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bac | 2015 |
Significant increase of serum prostate-specific antigen after exercise.
Topics: Acute Disease; Ciprofloxacin; Exercise; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antige | 2016 |
Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea.
Topics: Acute Disease; Adult; Age Factors; Aged; Amikacin; Anti-Bacterial Agents; Bacterial Infections; beta | 2016 |
Rectal Culture-Guided Targeted Antimicrobial Prophylaxis Reduces the Incidence of Post-Operative Infectious Complications in Men at High Risk for Infections Submitted to Transrectal Ultrasound Prostate Biopsy - Results of a Cross-Sectional Study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxaci | 2017 |
Anti-inflammatory and antimicrobial effects of garlic and synergistic effect between garlic and ciprofloxacin in a chronic bacterial prostatitis rat model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Synergism; Escherichia c | 2009 |
Ciprofloxacin induced tendinitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Humans; Male; Prostatitis; Tendinopathy; Treatment Outc | 2009 |
Re: Stancik et al: Effect of antibiotic therapy on interleukin-6 in fresh semen and postmasturbation urine samples of patients with chronic prostatitis/chronic pelvic pain syndrome. (Urology 2008;72: 336-339).
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Interleukin-6; Male; Masturbation; Prostatitis; Semen | 2009 |
Fluoroquinolone treatment of chronic bacterial prostatitis: a prospective cohort study.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cohort Studies; Fluoroquinolones; Humans; Male; Middle | 2009 |
[Chronic prostatitis and biofilm].
Topics: Adult; Biofilms; Chronic Disease; Ciprofloxacin; Contraception Behavior; Diet; Disease Susceptibilit | 2009 |
Do Escherichia coli extract and cranberry exert preventive effects on chronic bacterial prostatitis? Pilot study using an animal model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Escherichia coli; Male; Pilot | 2011 |
Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatment.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy; Carbapenems; Cef | 2012 |
Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Enterococcus fa | 2011 |
Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Chronic Disease; Ciprofloxacin; Cohort St | 2011 |
Preventive effect of selenium on chronic bacterial prostatitis.
Topics: Animals; Body Weight; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; Escherichia coli; Esc | 2012 |
Preventive effect of ginsenoid on chronic bacterial prostatitis.
Topics: Animals; Anti-Bacterial Agents; Body Weight; Ciprofloxacin; Colony Count, Microbial; Inflammation; M | 2012 |
Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis.
Topics: Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Cost-Benefit Analysis; | 2002 |
Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; | 2002 |
Transrectal prostatic ultrasonography in acute bacterial prostatitis: findings and clinical implications.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Bacterial Infections; Ceftriaxone; Ciprofloxacin; | 2003 |
Diagnosis and follow-up of acute bacterial prostatitis and orchiepididymitis detected by In-111-labeled leukocyte imaging.
Topics: Acute Disease; Bacterial Infections; Ciprofloxacin; Epididymitis; Follow-Up Studies; Humans; Indium | 2003 |
Imaging seminal vesiculitis with Tc-99m ciprofloxacin.
Topics: Ciprofloxacin; Humans; Infections; Male; Middle Aged; Organotechnetium Compounds; Prostatitis; Radio | 2003 |
[Infectious distribution and resistant of Neisseria gonorrhoeae, Mycoplasma, and Chlamydia trachomatis in the chronic prostatitis].
Topics: Adult; Chlamydia Infections; Chlamydia trachomatis; Chronic Disease; Ciprofloxacin; Erythromycin; Go | 2003 |
The rapid development of fluoroquinolone resistance in M. tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, | 2003 |
Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess.
Topics: Abscess; Adult; Bacteremia; Ciprofloxacin; Combined Modality Therapy; Community-Acquired Infections; | 2004 |
Summaries for patients. Treating men with chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Double-B | 2004 |
Treating chronic prostatitis: antibiotics no, alpha-blockers maybe.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Humans; Male; P | 2004 |
Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model.
Topics: Animals; Anti-Infective Agents; Catechin; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; D | 2005 |
[A young athletic man with dysuria and shivering].
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Ciprofloxacin; Diagnosis, Differential; Follow-Up Studi | 2005 |
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; | 2006 |
Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Algorithms; Androgen Antagonists; Anti-Bacterial Agents; | 2007 |
Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Androgen Antagonists; Anti-Bacterial Agents; Anti-Infective Age | 2007 |
Synergistic effect between lycopene and ciprofloxacin on a chronic bacterial prostatitis rat model.
Topics: Animals; Anti-Bacterial Agents; Carotenoids; Ciprofloxacin; Colony-Forming Units Assay; Disease Mode | 2008 |
Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Bacteria; Cephalosporins; Ciprofloxacin; Drug Resistan | 2008 |
Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Escherichia coli; Gram-Positive Bacteria; Humans; Levofloxacin | 2008 |
Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens.
Topics: Aged; Anti-Infective Agents, Urinary; Ciprofloxacin; Enterobacteriaceae; Enterococcus faecalis; Huma | 1984 |
Treatment of urinary tract infections with ciprofloxacin after renal transplantation.
Topics: Administration, Oral; Adult; Bacterial Infections; Bacteriuria; Ciprofloxacin; Cystitis; Female; Hum | 1993 |
Criteria for use of intravenous ciprofloxacin for infections in adult patients.
Topics: Adult; Ciprofloxacin; Drug Resistance, Microbial; Humans; Male; Prostatitis; Pseudomonas Infections; | 1993 |
[Ciprofloxacin-associated bilateral acute achilles tendinitis].
Topics: Achilles Tendon; Adult; Anti-Infective Agents; Ciprofloxacin; Humans; Male; Prostatitis; Tendinopath | 1995 |
Detection and follow-up of Wegener's prostatitis by transrectal ultrasound.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antirheumatic Agents; Ciprofloxacin; Cyclophosphami | 1998 |
National guideline for the management of prostatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
Topics: Adrenergic alpha-Antagonists; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, U | 1999 |
Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli | 2002 |
Imaging prostatitis with Tc-99m ciprofloxacin.
Topics: Acute Disease; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Male; Organotechnetium | 2002 |
Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months.
Topics: Administration, Oral; Adult; Chronic Disease; Ciprofloxacin; Drug Evaluation; Escherichia coli Infec | 1991 |
MICs of ciprofloxacin and trimethoprim for Escherichia coli: influence of pH, inoculum size and various body fluids.
Topics: Animals; Body Fluids; Chronic Disease; Ciprofloxacin; Dogs; Dose-Response Relationship, Drug; Escher | 1991 |
New 4-quinolones in the treatment of urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Combinations; Humans; Male; Norfloxacin; Pefloxa | 1986 |
Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Cystitis; Drug | 1986 |
Diffusion of ciprofloxacin into prostatic fluid.
Topics: Ciprofloxacin; Diffusion; Humans; Male; Prostatitis; Semen | 1988 |